Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis invests in Selexys with exclusive option to acquire the company; option exercised

Executive Summary

Novartis Pharmaceuticals Corp. has been granted an exclusive option to acquire closely held Selexys Pharmaceuticals Corp. (therapeutics for inflammatory and thrombotic diseases) after it completes a Phase II study of the anti-P-selectin antibody SelG1, which recently finished Phase I for vaso-occlusive crisis, a major complication in patients with sickle cell disease.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • Includes Equity

Related Companies